Last reviewed · How we verify
14C-FYU-981
14C-FYU-981 is a selective and potent inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2).
14C-FYU-981 is a selective and potent inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.
At a glance
| Generic name | 14C-FYU-981 |
|---|---|
| Sponsor | Fuji Yakuhin Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
SGLT2 is a key regulator of glucose reabsorption in the kidneys. By inhibiting SGLT2, 14C-FYU-981 reduces glucose reabsorption, leading to increased glucose excretion in the urine and lowering blood glucose levels.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Hypotension
Key clinical trials
- Mass Balance Study of FYU-981 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 14C-FYU-981 CI brief — competitive landscape report
- 14C-FYU-981 updates RSS · CI watch RSS
- Fuji Yakuhin Co., Ltd. portfolio CI